A.P. Pharma: Side Effect Issue With Competitive Drug Is A Huge Positive

Mon, 07/02/2012 - 06:18 EDT - Seeking Alpha

By Smith On Stocks:
Investment Thesis
The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran) to QT interval prolongation; this condition can cause abnormal heart rhythms that in some cases may be life threatening. This follows a previous communication on the same concern on September 11, 2011. Because AP Pharma's (APPA.OB) competitive product in development, APF530, is not linked to QT interval prolongation, this gives APF530 a meaningful differentiation from ondansetron in terms of safety. In addition, ondansetron can no longer be given as a single 32 mg infusion and will now have to be given in roughly three infusions over a twelve hour period. Some contacts I have spoken with think that these factors will cause a major erosion in ondansetron sales. If their assessment is correct, this could be a huge positive for A.P. Phama as ondansetron currently accounts for one thirdComplete Story »

Original article
Login or register to post comments

Doctors Think This Woman's Heart Problems Came From Drinking Only Soda For 16 Years
A 31-year old woman's heart problems and fainting might have had something to do with the fact that she drank only soda for about half her life, according to a report of her case. The woman, who lives in Monaco, a small country near southern France, was brought to a hospital after she fainted.
ER visits linked to energy drinks doubled since 2007, according to government survey
SAN FRANCISCO — A new government survey suggests the number of people seeking emergency treatment after consuming energy drinks has doubled nationwide during the past four years, the same period in which the supercharged drink industry has surged in popularity in convenience stores, bars and on college campuses.
FDA Considers Yanking Abbott's Diet Pill
Pharmalot submits: Eight months after their European counterparts told doctors to stop prescribing Abbott Labs’ (ABT) Meridia diet pill, the FDA will now ask an advisory panel meeting this Wednesday whether the drug should be withdrawn from the US market.
Eurozone Retail Sales Drop 8th Month; Italy, France are Down; Germany Retail Sales Up, Outlook Down
German retail sales bounced back for the second month, but not enough to prevent the aggregate eurozone sales from falling for the eighth consecutive month. Summary of June findings:
AP Pharma's APF530 Poised To Return To FDA Review
By Andrew McDonald:AP Pharma (APPA.PK) intends to resubmit the New Drug Application (NDA) for APF530 in 1H12 after working quietly and diligently on addressing all the issues raised in a March 2010 complete response letter (CRL), which the FDA issued in response to the original NDA filing (May 2009).
US warns of liver damage with heart drug
A heart drug by French pharmaceutical giant Sanofi-Aventis has been linked to liver damage in some patients, two of whom had to receive transplants, the US Food and Drug Administration said Friday.Dronedarone, marketed as Multaq, was approved in 2009 and has been prescribed at least 492,000 times to people in the United States for treating abnormal heart rhythm.The FDA issued its warning to the public and to health professionals, saying labels to the medication would be changed to advise of possible liver dangers.
Drug Linked To Deaths In US Military Kills London Marathoner Mid-Run
A young runner who collapsed and died during the London marathon had "significant" levels of a banned amphetamine-like fatburning supplement in her system, an inquest has heard. Claire Squires, 30, suffered a cardiac arrest outside Buckingham Palace, where she was treated in a medical tent before being rushed to hospital.
A.P. Pharma: PDUFA Date On APF530 Looms And I Am A Buyer
By Smith On Stocks: Investment Opinion and Background
Vibex MTX: The Cherry On Top Of The Antares Investment Story
By Smith On Stocks: Investment Thesis
Arena’s Diet Pill May Encounter Yet Another Issue: Heart Valve Disease
Pharmalot submits: When the FDA issued a complete response letter last month for the Arena Pharmaceutical (ARNA) diet pill, the agency cited a few reasons: pending results of a trial in 604 patients with diabetes, concerns that the pill may cause tumors in rats and efficacy was marginal (look here).

Main menu

Secondary menu

A.P. Pharma: Side Effect Issue With Competitive Drug Is A Huge Positive

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu